Monte Rosa Net Worth
Monte Rosa Net Worth Breakdown | GLUE |
Monte Rosa Net Worth Analysis
Monte Rosa's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Monte Rosa's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Monte Rosa's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Monte Rosa's net worth analysis. One common approach is to calculate Monte Rosa's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Monte Rosa's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Monte Rosa's net worth. This approach calculates the present value of Monte Rosa's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Monte Rosa's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Monte Rosa's net worth. This involves comparing Monte Rosa's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Monte Rosa's net worth relative to its peers.
Enterprise Value |
|
To determine if Monte Rosa is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Monte Rosa's net worth research are outlined below:
| Monte Rosa is way too risky over 90 days horizon | |
| Monte Rosa appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (135.35 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Monte Rosa Therapeutics currently holds about 294.14 M in cash with (43.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.32. | |
| Monte Rosa has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Monte Rosa Therapeutics Trading 9 percent Higher Time to Buy |
Monte Rosa uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Monte Rosa Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Monte Rosa's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Monte Rosa's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Monte Rosa is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Monte Rosa Therapeutics backward and forwards among themselves. Monte Rosa's institutional investor refers to the entity that pools money to purchase Monte Rosa's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Vestal Point Capital Lp | 2024-06-30 | 890 K | Geode Capital Management, Llc | 2024-06-30 | 847.4 K | State Street Corp | 2024-06-30 | 636.1 K | Exoduspoint Capital Management, Lp | 2024-09-30 | 393.6 K | Sphera Funds Management Ltd. | 2024-06-30 | 375 K | Northern Trust Corp | 2024-09-30 | 358.6 K | Charles Schwab Investment Management Inc | 2024-09-30 | 346.5 K | Renaissance Technologies Corp | 2024-09-30 | 218.7 K | Td Asset Management Inc | 2024-09-30 | 193.7 K | Nea Management Company, Llc | 2024-06-30 | 7.7 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 6 M |
Follow Monte Rosa's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 513.61 M.Market Cap |
|
Project Monte Rosa's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.45) | (0.47) | |
| Return On Capital Employed | (0.56) | (0.59) | |
| Return On Assets | (0.45) | (0.47) | |
| Return On Equity | (0.76) | (0.72) |
When accessing Monte Rosa's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Monte Rosa's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Monte Rosa's profitability and make more informed investment decisions.
Please note, the presentation of Monte Rosa's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Monte Rosa's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Monte Rosa's management manipulating its earnings.
Evaluate Monte Rosa's management efficiency
Monte Rosa Therapeutics has return on total asset (ROA) of (0.2843) % which means that it has lost $0.2843 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6123) %, meaning that it created substantial loss on money invested by shareholders. Monte Rosa's management efficiency ratios could be used to measure how well Monte Rosa manages its routine affairs as well as how well it operates its assets and liabilities. As of November 21, 2024, Return On Tangible Assets is expected to decline to -0.47. In addition to that, Return On Capital Employed is expected to decline to -0.59. At present, Monte Rosa's Other Current Assets are projected to increase significantly based on the last few years of reporting.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.49 | 2.45 | |
| Tangible Book Value Per Share | 3.49 | 2.45 | |
| Enterprise Value Over EBITDA | (1.52) | (1.60) | |
| Price Book Value Ratio | 1.62 | 1.70 | |
| Enterprise Value Multiple | (1.52) | (1.60) | |
| Price Fair Value | 1.62 | 1.70 | |
| Enterprise Value | 208.3 M | 197.9 M |
Monte Rosa Therapeutics benefits from a management team that prioritizes both innovation and efficiency. We analyze these priorities to gauge the stock's future performance.
Enterprise Value Revenue 21.0433 | Revenue 15 M | Revenue Per Share 0.221 | Return On Equity (0.61) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Monte Rosa insiders, such as employees or executives, is commonly permitted as long as it does not rely on Monte Rosa's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Monte Rosa insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Monte Rosa Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 30th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 12th of August 2024 An amendment to the original Schedule 13D filing | ViewVerify |
Monte Rosa Earnings per Share Projection vs Actual
Monte Rosa Corporate Management
| Filip MD | Chief Officer | Profile | |
| Jennifer Champoux | VP Operations | Profile | |
| Sharon Townson | Chief Officer | Profile | |
| Edmund Dunn | Vice Controller | Profile | |
| John Castle | Chief Scientist | Profile | |
| Magnus DPHIL | Senior Development | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monte Rosa. If investors know Monte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monte Rosa listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Revenue Per Share 0.221 | Return On Assets (0.28) | Return On Equity (0.61) |
The market value of Monte Rosa Therapeutics is measured differently than its book value, which is the value of Monte that is recorded on the company's balance sheet. Investors also form their own opinion of Monte Rosa's value that differs from its market value or its book value, called intrinsic value, which is Monte Rosa's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monte Rosa's market value can be influenced by many factors that don't directly affect Monte Rosa's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.